Standout Papers

Psoriatic Arthritis 2005 2026 2012 2019 890
  1. Psoriatic Arthritis (2017)
    Christopher T. Ritchlin, Robert A. Colbert et al. New England Journal of Medicine
  2. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial (2005)
    Philip J. Mease, Dafna D. Gladman et al. Arthritis & Rheumatism
  3. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial (2015)
    Iain B. McInnes, Philip J. Mease et al. The Lancet
  4. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial (2013)
    Iain B. McInnes, Arthur Kavanaugh et al. The Lancet
  5. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial (2014)
    Christopher T. Ritchlin, Proton Rahman et al. Annals of the Rheumatic Diseases
  6. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 (2016)
    Philip J. Mease, Désirée van der Heijde et al. Annals of the Rheumatic Diseases
  7. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial (2020)
    Atul Deodhar, Philip Helliwell et al. The Lancet

Immediate Impact

2 by Nobel laureates 14 from Science/Nature 67 standout
Sub-graph 1 of 19

Citing Papers

Fibroblast and myofibroblast activation in normal tissue repair and fibrosis
2024 Standout
Cellular and molecular mechanisms of skin wound healing
2024 Standout
5 intermediate papers

Works of Christopher T. Ritchlin being referenced

Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis
2009
MRI and Quantification of Draining Lymph Node Function in Inflammatory Arthritis
2007
and 6 more

Author Peers

Author Last Decade Papers Cites
Christopher T. Ritchlin 9763 9281 5243 342 14.7k
Dominique Baeten 9527 8047 3757 322 15.7k
Oliver FitzGerald 8496 6702 3792 468 14.2k
Proton Rahman 7370 6636 3378 308 10.6k
Alan Kivitz 7180 4379 3209 264 12.4k
Filip Van den Bosch 8534 5191 3463 298 10.6k
Arthur Kavanaugh 8542 7984 4789 309 12.1k
Mark C. Genovese 13775 8351 6345 315 22.2k
Douglas J. Veale 6204 4198 2161 284 12.7k
Barry Bresnihan 7141 3964 2233 231 12.6k
Joachim R. Kalden 8278 4362 3477 159 13.2k

All Works

Loading papers...

Rankless by CCL
2026